AD-O53.2-novel biological anticancer therapeutic agent with a dual mechanism of action

被引：0
|
作者：
Poleszak, K. [1 ]
Pieczykolan, J. [1 ]
Pawlak, S. [1 ]
Zerek, B. [1 ]
Rozga, P. [1 ]
Teska-Kaminska, M. [1 ]
Galazka, M. [1 ]
Szymanik, M. [1 ]
Jaworski, A. [1 ]
Pieczykolan, A. [1 ]
Bukato, K. [1 ]
Strozek, W. [1 ]
机构：
[1] Adamed Sp Zoo, Drug Discovery, Warsaw, Poland
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70645-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
519
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [1] Biochemical and biophysical characterization of AD-O51.4 a novel anticancer biological therapeutic agent with dual mechanism of action
    Pawlak, Sebastian D.
    Pieczykolan, Jerzy S.
    Zerek, Bartlomiej
    Poleszak, Katarzyna
    Teska-Kaminska, Malgorzata
    Galaska, Marlena
    Szymanik, Michal
    Jaworski, Albert
    Pieczykolan, Anna
    Bukato, Katarzyna
    Strozek, Wojciech
    Rozga, Piotr K.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II α
    Jensen, LH
    Renodon-Cornière, A
    Nitiss, KC
    Hill, BT
    Nitiss, JL
    Jensen, PB
    Sehested, M
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (04) : 623 - 631
  • [3] Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
    Hallakou-Bozec, Sophie
    Vial, Guillaume
    Kergoat, Micheline
    Fouqueray, Pascale
    Bolze, Sebastien
    Borel, Anne-Laure
    Fontaine, Eric
    Moller, David E.
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 664 - 673
  • [4] EXPERIMENTAL ANTITUMOUR ACTIVITY AND MECHANISM OF ACTION OF THE NOVEL ANTICANCER AGENT CCRG-81010
    WORKMAN, P
    LEE, FYF
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 251 - 252
  • [5] Anticancer agent leinamycin may have dual mechanism
    不详
    CHEMICAL & ENGINEERING NEWS, 1997, 75 (49) : 23 - 23
  • [6] MODELS FOR A HYPOTHETICAL MECHANISM OF ACTION OF THE ANTICANCER AGENT VINBLASTINE
    MAGNUS, P
    LADLOW, M
    ELLIOTT, J
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1987, 109 (25) : 7929 - 7930
  • [7] Preclinical evaluation of anticancer potential of AD-O51.4-novel fusion molecule with dual antiangiogenic and anticancer potential
    Pieczykolan, J.
    Rozga, P.
    Pieczykolan, A.
    Pawlak, S.
    Zerek, B.
    Glazka, M.
    Bukato, K.
    Szymanik, M.
    Jaworski, A.
    Grochot-Przeczek, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S127 - S127
  • [8] Dual pH-sensitive oxidative stress generating micellar nanoparticles as a novel anticancer therapeutic agent
    Park, Sanga
    Kwon, Byeongsu
    Yang, Wonseok
    Han, Eunji
    Yoo, Wooyoung
    Kwon, Byoung-Mog
    Lee, Dongwon
    JOURNAL OF CONTROLLED RELEASE, 2014, 196 : 19 - 27
  • [9] Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
    Álvaro Pinto
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 219 - 222
  • [10] Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
    Pinto, Alvaro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 219 - 222
12345